Jounce Therapeutics to Participate in Cowen & Co. 42nd Annual Health Care Conference

Rhea-AI Summary

Jounce Therapeutics (NASDAQ: JNCE) announced its participation in a novel immuno-oncology panel at the Cowen & Co. 42nd Annual Health Care Conference on March 7, 2022, at 10:30 a.m. ET. The session will be accessible via webcast on Jounce's website, with a replay available for 30 days post-event. Jounce is focused on developing cancer immunotherapies and currently advancing programs like JTX-8064, a receptor antagonist targeting immune-suppressive tumor macrophages, and vopratelimab, an ICOS-activating monoclonal antibody.

CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will participate in a novel immuno-oncology panel discussion at the Cowen & Co. 42^nd Annual Health Care Conference on Monday, March 7, 2022 at 10:30 a.m. ET.

A webcast of the panel will be available by visiting “Events and Presentations” in the Investors and Media section of Jounce’s website at www.jouncetx.com. A replay of the webcasts will be archived for 30 days following the presentation.

About Jounce Therapeutics
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce’s highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. JTX-8064 is currently being investigated alone and in combination with pimivalimab (formerly JTX-4014), Jounce’s internal PD-1 inhibitor, in one monotherapy and seven combination indication-specific expansion cohorts in the Phase 1/2 INNATE trial and is currently enrolling patients with advanced solid tumors in the Phase 2 portion of the study. Jounce’s most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. Pimivalimab is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce’s broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to GS-1811 (formerly JTX-1811), a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc. For more information, please visit www.jouncetx.com.

Investor and Media Contact:
Eric Laub
+1-857-259-3853
elaub@jouncetx.com 

FAQ

What is the date and time of Jounce Therapeutics' panel discussion at the Cowen & Co. conference?

Jounce Therapeutics will participate in the panel discussion on March 7, 2022, at 10:30 a.m. ET.

How can I access the webcast of Jounce Therapeutics' panel discussion?

The webcast can be accessed through the 'Events and Presentations' section on Jounce's website.

What key programs is Jounce Therapeutics currently developing?

Jounce is focusing on JTX-8064, a receptor antagonist targeting tumor macrophages, and vopratelimab, an ICOS-activating monoclonal antibody.

How long will the replay of the Jounce Therapeutics panel discussion be available?

The replay of the webcast will be available for 30 days following the presentation.

What is Jounce Therapeutics' primary focus in cancer treatment?

Jounce Therapeutics focuses on developing cancer immunotherapies and predictive biomarkers to enable the immune system to attack tumors.